Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume - Time to Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) saw an uptick in trading volume on Friday . 353,339 shares changed hands during trading, an increase of 39% from the previous session's volume of 254,297 shares.The stock last traded at $21.99 and had previously closed at $22.04.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird increased their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday, November 15th. HC Wainwright reiterated a "buy" rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Finally, BTIG Research started coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a "buy" rating and a $42.00 price target for the company. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of "Buy" and a consensus target price of $38.25.

Enliven Therapeutics Stock Down 0.8 %

The company's 50-day moving average is $23.44 and its two-hundred day moving average is $24.37. The company has a market capitalization of $1.07 billion, a P/E ratio of -11.51 and a beta of 1.04.

Insider Transactions at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 6,250 shares of the company's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $28.56, for a total value of $178,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Anish Patel sold 21,700 shares of the firm's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $24.18, for a total value of $524,706.00. The disclosure for this sale can be found here. Insiders have sold 38,450 shares of company stock valued at $953,380 in the last quarter. Insiders own 29.20% of the company's stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in the business. American Century Companies Inc. boosted its stake in shares of Enliven Therapeutics by 44.7% during the second quarter. American Century Companies Inc. now owns 27,651 shares of the company's stock valued at $646,000 after purchasing an additional 8,540 shares during the period. Marshall Wace LLP purchased a new stake in Enliven Therapeutics during the 2nd quarter valued at $4,489,000. The Manufacturers Life Insurance Company bought a new stake in Enliven Therapeutics in the 2nd quarter worth $322,000. SG Americas Securities LLC purchased a new position in shares of Enliven Therapeutics in the third quarter valued at about $256,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock valued at $232,000 after acquiring an additional 3,559 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.